Press Releases Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None2026202520242023202220212020 February 26, 2025 Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference February 5, 2025 Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference January 13, 2025 Protara Highlights Recent Updates and Anticipated 2025 Milestones January 8, 2025 Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference December 11, 2024 Protara Announces Closing of $100 Million Public Offering December 9, 2024 Protara Announces Pricing of $100 Million Public Offering December 9, 2024 Protara Announces Proposed Public Offering December 5, 2024 Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC December 3, 2024 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024 November 15, 2024 Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology November 12, 2024 Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update November 6, 2024 Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 37 - 48 of 132 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None2026202520242023202220212020 February 26, 2025 Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference February 5, 2025 Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference January 13, 2025 Protara Highlights Recent Updates and Anticipated 2025 Milestones January 8, 2025 Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference December 11, 2024 Protara Announces Closing of $100 Million Public Offering December 9, 2024 Protara Announces Pricing of $100 Million Public Offering December 9, 2024 Protara Announces Proposed Public Offering December 5, 2024 Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC December 3, 2024 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024 November 15, 2024 Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology November 12, 2024 Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update November 6, 2024 Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 37 - 48 of 132
February 5, 2025 Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
December 5, 2024 Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
December 3, 2024 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024
November 15, 2024 Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
November 12, 2024 Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
November 6, 2024 Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
